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Abstract
Retinitis pigmentosa (RP) is a group of genetically and clinically heterogeneous inherited
retinal degenerative diseases with no known cure to date. The recent gene therapy treatment
for Leber’s congenital amaurosis and RP caused by mutations in RPE65 have resulted in
dramatic improvements in vision, leading to excitement for other potential gene therapies on
the horizon. Upcoming clinical trials will be targeting patients with specific mutations, and
measurements of disease progression will be needed for each genetic subtype of RP in
order to determine whether treatments are successful. In this retrospective cohort study, we
examined 27 RP patients with confirmed autosomal dominant mutations in the rhodopsin
gene by monitoring rates of progression as measured structurally with ellipsoid zone (EZ)
line width on spectral domain optical coherence tomography (SD-OCT), horizontal and
vertical hyperautofluorescent ring diameters on short wavelength fundus autofluorescence
(SW-FAF), and as measured functionally with 30 Hz flicker amplitudes on
electroretinography (ERG). Each structural parameter was measured twice by the author
four weeks apart. The mean rates of progression were -158.5 μm per year (-8.4%) for EZ
line widths, -122.7 μm per year (-3.5%) for horizontal diameters, and -108.3 μm per year
(-3.9%) for vertical diameters. High test-retest reliability was observed for the parameters (EZ
line intraclass coefficient [ICC] = 0.9989, horizontal diameter ICC = 0.9889, vertical diameter
ICC = 0.9771). The three parameters were also correlated with each other (r = 0.9325 for EZ
line and horizontal diameter; r = 0.9081 for EZ line and vertical diameter; r = 0.9630 for
horizontal and vertical diameters). No significant changes in ERG amplitude were seen. The
subjects were classified by rhodopsin mutation class (I, IIa, IIb, III) and morphology of the
hyperautofluorescent ring (typical vs. atypical). No significant differences in rates of structural
progression were observed by rhodopsin mutation class or by ring morphology. Finally,
higher rates of asymmetry of progression between the left and right eyes were detected for
EZ line width (23% of subjects), horizontal diameter (17%), and vertical diameter (25%), as
compared to studies on other forms of RP.
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Introduction

Retinitis pigmentosa (RP), a group of inherited retinal diseases with an incidence
of approximately one in 4000 people, is characterized by progressive
photoreceptor death and irreversible vision loss (1). Typically, the initial loss of
photoreceptors primarily involves the rods, thereby diminishing peripheral and
night vision, followed by worsening tunnel vision and eventual loss of central
vision mediated by cone photoreceptor death (1). Ophthalmoscopic hallmarks of
the disease include retinal arteriolar attenuation, bone-spicule peripheral pigment
deposits, and waxy pallor of the optic disc (2). The clinical presentation of retinitis
pigmentosa is highly variable. The severity and pattern of vision loss may be mild
or severe. The rate of disease progression can be slow or rapid, and the age of
onset can be as early as childhood while some individuals remain asymptomatic
until mid-adulthood. Allelic heterogeneity, in which each gene locus may have
different mutations that cause the same disease entity, contributes to the diverse
genetic etiology of RP; for example, over 300 different RPGR mutations have
been identified in families with X-linked RP (3). Even among members of the
same family, the same mutation may result in different phenotypic
manifestations. RP is also a genetically heterogeneous disease, with over 50
genes that have been found to be associated with non-syndromic RP. Further
complicating the heterogeneity of the disease is that different mutations in the
same gene may result in different modes of inheritance. The pattern of
inheritance can be autosomal recessive (15-20%), autosomal dominant (20-
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25%), X-linked recessive (10-15%), or sporadic (30%) (2, 4). RP may also be
syndromic, as seen in Bardet-Biedl syndrome, Usher syndrome,
abetalipoproteinemia (Bassen-Kornzweig syndrome), and phytanic acid oxidase
deficiency (Refsum disease) (2).

Despite the genetic complexity of RP, improvements in the cost and efficiency of
molecular techniques that allow for the high-throughput DNA sequencing of
patients have resulted in clinicians being able to append a molecular diagnosis to
their clinical diagnosis. Specifically, the advent of next-generation sequencing
(NGS), which is able to perform massively parallel sequencing runs on the order
of millions of DNA fragments using micron-sized beads, has dramatically
increased the speed of sequencing many-fold and enabled the capture of a
broader spectrum of mutations compared to conventional Sanger sequencing (5).

Molecular basis of the visual cycle

To understand how mutations in certain genes may cause RP, an outline of the
visual cycle will need to be described. The first step in vision occurs when light
enters the eye and is focused by the cornea and lens onto the retina
(photosensitive tissue located posteriorly within the eye). In the retina, the lightsensitive photoreceptor cells called rods and cones convert the external light
stimuli into electrical impulses that the brain processes to form an image. Rod
photoreceptors contain the visual pigment rhodopsin, which is a light-sensitive G-
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protein coupled receptor that consists of the apoprotein opsin and 11-cis-retinal,
a chromophore. When light is absorbed by rhodopsin, the 11-cis-retinal is
converted to all-trans-retinal and leads to a series of conformational changes of
the opsin that activates the GTP-binding protein transducin, triggering a
canonical cyclic guanosine monophosphate (cGMP) second-messenger cascade
through the activation of cGMP phosphodiesterase (PDE) (2). PDE hydrolyzes
cGMP, leading to closure of the cGMP-dependent cation channels normally
responsible for influx of Na+, Ca2+, and Mg2+. The resulting hyperpolarization of
the photoreceptor cell decreases the rate of transmitter release and elicits
responses in second-order (bipolar) cells for further neural transmission (6). The
all-trans-retinal is converted to all-trans-retinol and is transported to the retinal
pigment epithelium (RPE) to be recycled into 11-cis-retinal for transport back into
the rods (2).

Rods are sensitive to low levels of light, and psychophysical experiments have
shown that they can register single photon absorptions (6). Since rods play a
crucial role in enabling vision in low-light scenarios and are anatomically located
in the periphery of the retina, RP patients usually experience night blindness
(nyctalopia) and loss of peripheral vision as their initial symptoms.

The organization of the rod photoreceptor consists of a synaptic body that
interfaces with the bipolar/horizontal cells, a cell body, an inner segment (IS)
which contains the endoplasmic reticulum, mitochondria, and Golgi apparatus,
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and an outer segment (OS) which houses membranous discs containing mostly
opsin within a plasma membrane. The IS and OS are connected by the
connecting cilium, and the OS interfaces with and is phagocytosed by the RPE.

Figure 1. a) Illustration showing cell organization within the retina. b) Crosssectional H&E stain of retina. Image from Wikimedia Commons.
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Structure of rhodopsin

As previously mentioned, rhodopsin (RHO) is the G-protein coupled receptor
(GPCR) that is responsible for the first step in allowing rod photoreceptors to
detect light. It is synthesized in the rough endoplasmic reticulum and then
transported through the Golgi apparatus where it ultimately functions within the
discs of the OS (7). 30% to 40% of all autosomal dominant RP (adRP) is caused
by mutations in the RHO gene, and over 120 different mutations in RHO have
been identified (2, 8). One study of 200 families with clinical evidence of adRP
found that rhodopsin mutations were the most common cause of disease,
representing 26.5% of the total cases of adRP (9). In addition to its role in adRP,
rhodopsin was the first GPCR whose crystal structure was elucidated, and it
served as a prototype template for understanding the rest of the GPCR
superfamily (8). Rhodopsin is a highly conserved protein among vertebrate
species, and similar proteins have even been found in the visual systems of
invertebrates such as Drosophila melanogaster (10). The structure of rhodopsin
consists of four specialized domains that assist in the maintenance of protein
structure, trafficking, and phototransduction: 1) cytoplasmic, 2) intradiscal, 3)
transmembrane, and 4) ligand-binding domains (11). The cytoplasmic C-terminal
domain of rhodopsin regulates its trafficking and interactions with other proteins
in the phototransduction cascade such as transducin (11). The intradiscal domain
contains the extracellular loops between transmembrane domains and the Nterminus. Research suggests that mutations in the intradiscal domain result in
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misfolding of the protein and accumulation of the protein within the secretory
system, leading to disease (12). The transmembrane domains have been shown
to have several residues that are important for rhodopsin protein stability and
function (13). The ligand-binding domain is where the 11-cis-retinal chromophore
binds with the opsin apoprotein (14).

Biochemical classification of rhodopsin mutations

Mutations in rhodopsin causing adRP have been grouped into three classes
(Table 1) based on the phenotypes of the proteins from in vitro studies that
transfected human tissue culture cells with wild-type and mutant rhodopsin cDNA
clones (8, 11, 12). Class I mutations are located near the C-terminus of the
protein or within the first transmembrane segment. The protein resembles wildtype rhodopsin in terms of protein levels, ability to associate with the 11-cisretinal chromophore, and subcellular localization (15, 16). However, these
mutations cause rhodopsin to activate transducin inefficiently in the presence of
light (17). Class II mutations cause decreased binding to 11-cis-retinal and result
in accumulation within the endoplasmic reticulum, possibly due to issues with
protein folding and stability (15, 17). Within class II, further subclassification can
be made for those mutants that predominantly localize intracellularly (class IIa)
and those that preferentially localize to the cell surface (class IIb) (16). Finally,
class III mutants form rhodopsin poorly and at low levels, are retained in the
endoplasmic reticulum, and may form aggresomes, causing targeted degradation
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by the ubiquitin proteasome system (18). Studies have suggested that impaired
endocytic activity is the primary mechanism by which class III mutations cause
RP (19). One common finding among all three classes of mutations is the
decreased sensitivity to light and less efficient activation of transducin (17).

Table 1. Classification and description of rhodopsin mutants
Class
Biochemical phenotype
Mutations occur near C-terminus
I
Similar to wild-type rhodopsin
Inefficient activation of transducin
Misfolding/instability
Accumulation within endoplasmic reticulum
II
Class IIa: localize intracellularly
Class IIb: localize to cell surface
Impaired endocytosis from membrane
III
Form rhodopsin chromophore poorly
Accumulation within endoplasmic reticulum

Clinical classification of rhodopsin patients

Aside from the preceding classification of rhodopsin mutations based on
biochemical characteristics, research on adRP caused by rhodopsin mutations
has produced evidence of two different subtypes predicated on the clinical
pattern of disease. The class A phenotype, sometimes referred to as “type 1” or
“diffuse” subtypes, is characterized by a severe, early-onset diffuse loss of rod
sensitivity with a later prolonged degeneration of cones (20, 21). The class B
phenotype, also known as “type 2” or “regional”, exhibits a combined loss of rod
and cone sensitivity in a superior hemifield (altitudinal) pattern with relatively
preserved function in the inferior hemifield, as well as a slower progression of
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disease with night blindness manifesting during adulthood (21). Because of the
regionalized retinal degeneration in the altitudinal pattern, these phenotypic
variants of RP are also known as sector RP (22). It has been postulated that the
more severe class A phenotype may be caused by a gain-of-function mutation
that is cytotoxic, while the milder class B phenotype is a result of a loss-offunction mutation inherited on a single allele (23).

Potential for therapeutic intervention

Gene therapy is an experimental technique that seeks to treat genetic disorders
by replacing or supplementing the mutated gene with a healthy copy of the gene,
or inactivating a mutated gene, in contrast to traditional therapies such as
surgery and medications. In late 2017, Spark Therapeutics’ LUXTURNA™
(voretigene neparvovec), a treatment for LCA and RP caused by mutations in the
RPE65 gene, became the first gene therapy for any disease to gain regulatory
approval in the United States by the Food and Drug Administration. This gene
therapy involves the subretinal injection of wild-type copies of RPE65 packaged
in an adeno-associated virus (AAV).

RPE65 (retinal pigment epithelium-specific protein, 65 kDa) is responsible for
producing the isomerase enzyme that catalyzes the isomerization of all-transretinal back to 11-cis-retinal within the retinal pigment epithelium so that the
previously mentioned visual cycle can begin again (24). In LCA and RP caused
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by bi-allelic mutations in RPE65, the visual cycle is disrupted and photoreceptors
undergo dysfunction and degeneration, the two pathological mechanisms that
ultimately lead to progressive blindness (25). Early preclinical studies in mouse
and dog models have shown that gene augmentation therapy is able to correct
the biochemical blockade and result in significant, persistent vision improvement
(25). These promising initial results over the past two decades led to the
University of Pennsylvania research group to collaborate with Spark
Therapeutics to test the efficacy and safety of AAV2-hRPE65v2 (voretigene
neparvovec) on 31 patients across two leading US academic centers for the
study of inherited retinal dystrophies (Children’s Hospital of Philadelphia,
Philadelphia, PA and University of Iowa, Iowa City, IA). This randomized
controlled study, the first phase 3 trial for any gene therapy, demonstrated
clinically and statistically significant improvements in the subjects’ visual field
measurements and ability to independently navigate in low-light conditions,
persisting throughout the one-year follow-up period (26).

The success of the RPE65 gene therapy trials has spawned a large number of
clinical trials seeking to use gene therapy to cure other inherited retinal
degenerative diseases. For example, there are several endeavors in the US and
the UK to study gene therapy treatments for choroideremia, an X-linked
recessive retinal disease that causes progressive loss of peripheral vision and
night blindness (27, 28). Choroideremia is caused by mutations in the CHM
gene, which encodes for the Rab escort protein-1 (REP1). This condition is
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amenable to treatment with gene therapy using an adeno-associated virus 2
(AAV2) capsid due to the relatively small size of the CHM cDNA payload that can
be contained with the AAV2 vector (28).

However, unlike the loss-of-function mutations of the recessive choroideremia
and LCA that can be addressed with simple replacement of the wild-type gene,
RP caused by a dominant RHO mutation acquires an abnormal gain of function
that requires suppression of the mutant RHO gene and replacement with the
wild-type version. Strategies for suppressing the toxic gene include
transcriptional silencing, RNA interference, and ablation or correction of the
mutation at the DNA level using gene editing techniques such as zinc finger
nucleases (ZFNs), transcription activator-like effector-based nucleases
(TALENs), and the recently discovered clustered regularly interspaced
palindromic repeats (CRISPR)/Cas9 system. For RHO-adRP specifically, efforts
over the past few decades have focused on either targeting specific mutant
alleles for reduction in expression levels or by implementing a mutationindependent knockdown strategy (29-31). The mutation-independent strategy is
particularly useful given the heterogeneity of the disease due to the large number
of disease-causing RHO mutations. This generally involves silencing the
expression of both the mutant and wild-type RHO alleles, while supplementing
wild-type protein-encoding RHO cDNA that is modified to be resistant to the
suppressor. Various methods exist to silence gene expression, including RNA
interference (RNAi) via short hairpin RNA (shRNA) or small interfering RNA
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(siRNA), CRISPR/Cas9, and TALENs (32). One way of conferring resistance to
the replacement RHO cDNA is to modify codons to contain wobble nucleotides at
the target site, thereby decreasing hybridization with the suppressor reagent (33).

The goal of finding treatments that are targeted to each specific genetic disorder
is timely given the launch of the United States Precision Medicine Initiative during
President Barack Obama’s tenure. There has been an increased interest among
the scientific and medical communities to discover “precision medicine”
treatments tailored to each individual’s variability in genes, environment, and
lifestyle (34). Given the inevitable progress within the next decade in the field of
gene therapy in the wake of LUXTURNA, there is a crucial obligation to
characterize the natural history progression of each disease on a gene-by-gene
basis. Without baseline measurements of disease progression rates and
asymmetry between eyes, it will be difficult to determine the efficacy of retinal
gene therapy even with an untreated control eye.

Structural and functional assessments

Various structural and functional measures of disease severity exist within the
field of ophthalmology. Visual acuity and visual field testing are able to capture
the patient’s perception of visual impairment, but they are subjective tests that
have low test-retest reliability (35, 36). An objective method of assessing visual
function is electroretinography (ERG). This noninvasive electrophysiologic test of
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retinal function uses recording electrodes placed on the corneal surface and
measures the changes in electric potential (against a reference electrode placed
on the skin) in response to light stimuli of varying intensities under dark- and
light-adapted conditions. The stimulation of the retina produces characteristic
waveforms that provide information about the function of different cells within the
retina, such as rods, cones, bipolar cells, retinal ganglion cells, and amacrine
cells. Important parameters of the waveform include the a- and b-wave
amplitudes (distance from baseline to a-wave trough, and from a-wave trough to
b-wave peak, respectively) and implicit time (time between stimulus onset and
maximum amplitude). The ERG is a useful tool in diagnosing many retinal
conditions, including retinitis pigmentosa, congenital stationary night blindness,
achromatopsia, toxic retinopathies, and cancer-associated retinopathy (37). It
also has utility in objectively assessing the retinal function in animal research
models. There are different forms of ERG, such as the standardized full-field
ERG (ffERG) which measures the total retinal response, pattern ERG (PERG)
which assesses central retinal function, and the multifocal ERG (mfERG) which
can detect localized responses in precise regions of the retina within the central
30 degrees (38). ERGs have shown increased reproducibility of measurements
compared to visual field testing, but are limited in their ability to reliably detect
small variations such as in end-stage retinal disease (35).

Imaging modalities such as spectral-domain optical coherence tomography (SDOCT) and fundus autofluorescence (FAF) have also been shown to be practical
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tools in providing data about retinal and RPE structures that correlate well with
disease progression and functional measures (39). With the loss of
photoreceptors in the periphery that gradually progresses towards the fovea seen
in RP, it is important to be able to visualize and differentiate between the
dysfunctional, diseased portions and the healthy viable regions of the retina. One
visual marker of this border is the parafoveal ring of increased autofluorescence
first shown to be correlated with PERG by Robson et al. in 2003 (40). The shortwavelength autofluorescence (SW-AF) imaging technique uses blue light
excitation at 488 nm and detects signals originating from lipofuscin granules and
other fluorophores within the RPE/photoreceptor complex (41). In RP patients,
these signals may manifest as rings and are thought to be the transition between
healthy and diseased retinal areas, with normal function within the ring and
dysfunction outside the ring (42). Some researchers have theorized that the
increased intensity of the autofluorescence signal is due to atrophy or stressinduced accumulation of lipofuscin – the oxidative byproduct of phagocytosed
photoreceptor outer segments – within the RPE (43). The maximum intensity of
the signal captured by FAF may therefore represent the distribution of active
degeneration of photoreceptors where there is a high rate of phagocytosis by the
RPE; dark areas seen on fundus autofluorescence are indicative of atrophy of
the RPE and corresponding loss of lipofuscin granules (44). Studies have
demonstrated that the rate of hyperautofluorescent ring constriction is correlated
with visual field loss progression and has prognostic value in predicting visual
field acuity and visual field preservation (45).
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In addition to FAF, SD-OCT is another noninvasive imaging modality that can
allow for in vivo visualization of the retinal layers. One hyperreflective band layer
that can provide information about photoreceptor health and function is the
ellipsoid zone (EZ), previously known as the inner segment/outer segment
(IS/OS) line (though the precise anatomic origins continue to be a topic of
debate). The hyperreflectivity of the EZ likely corresponds with the light scattering
by the mitochondria within the distal portion of the inner segment (46). Disruption
and/or shortening of the EZ line width corresponds with loss of visual field
sensitivity and thus provides a structural marker for the visual field edge (47, 48).
Some studies have shown that measurement of the EZ line width may be more
sensitive than full-field ERG and standard visual field testing in detecting
progression of visual field changes in RP. Birch et al. found that the rate of
change in EZ line width is consistent with those reported for ERGs and visual
fields, yet the test-retest variability of the EZ line width was considerably lower
(39). Furthermore, Birch et al. showed that the edge of the EZ line is where the
visual field sensitivity changes most accurately, and that observing this region is
more sensitive in detecting disease progression than global measurements that
average across the entire field (i.e., monitoring the healthy macula and the
diseased periphery, which are relatively stable) (49).
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Figure 2. SD-OCT image showing retinal layers. Red arrow heads pointing to ellipsoid zone line
layer (top). Measurement of ellipsoid zone line width between dotted lines (bottom).
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Statement of Purpose

Retinitis pigmentosa (RP) is a group of inherited retinal degenerative diseases affecting
roughly one in 4000 people worldwide and manifests as a progressive loss of vision. The
pattern of visual loss generally involves the initial degeneration of the rod
photoreceptors, followed by loss of the cones. It is marked by clinical and genetic
heterogeneity, with varying rates of vision loss and levels of disease severity, different
modes of inheritance, and more than 100 genes whose mutations have been found to
cause RP. There is currently no known cure for RP, but the recent groundbreaking FDAapproved gene therapy treatment (LUXTURNA™) for Leber’s congenital amaurosis and
RP caused by mutations in RPE65 has shown dramatic improvements in vision and
given promise that gene therapy is a viable strategy for treating inherited retinal
diseases.

For future gene therapy clinical trials, it will be crucial to have data regarding RP natural
disease history and appropriate outcome measurements on a gene-by-gene basis given
the heterogeneity of the disease. Furthermore, precise details about disease severity
based on the various types of mutations within a single gene would inform researchers
about their decisions to enroll patients with certain mutations. In this study, we seek to
examine a subset of autosomal dominant RP patients with known mutations in the
rhodopsin gene (RHO) using structural (ellipsoid zone line width, hyperautofluorescent
ring diameters) and functional (electroretinography) assessments to monitor disease
progression. We will also look for asymmetry of rates between eyes and any correlations
between the rhodopsin mutation class, morphology of the hyperautofluorescent ring, and
disease severity.
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Methods
Subjects

This study was conducted in adherence to the tenets of the Declaration of
Helsinki. All study procedures were defined and approved by the Institutional
Review Board at the Edward Harkness Eye Institute and Columbia University
Medical Center (Protocol #AAAR0284). Patient consent was obtained from all
subjects. The patient data presented here, including images and genetic testing
results, are not identifiable to individual patients. Diagnoses of RP were made by
an inherited retinal disease specialist (S.H.T.) based on clinical history, fundus
examinations, and full-field electroretinography (ffERG) results. This is a
retrospective cohort study with the following inclusion criteria: 1) patients must
have genetic sequencing-confirmed RHO mutations; and 2) a complete
ophthalmic examination must have been performed by our retinal disease
specialist on at least one visit. Since our clinic is an international referral center
for patients with RP, a significant portion of the subjects had their care
transferred back to their primary provider after the initial diagnosis was made in
our clinic using imaging, electroretinography, and genetic testing and thus did not
return for a follow-up visit. Patients were excluded if they: 1) presented with
advanced stage RP with no visible ellipsoid zone line in any eye at all time
points; 2) had unilateral RP; 3) did not have any visible hyperautofluorescent ring
in any eye at all time points; and 4) had poor image quality. A total of 38 patients
fit our inclusion criteria; 11 patients were excluded based on the exclusion
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criteria, leaving a total of 27 patients on whom to base our analysis. The 38
patients belonged to 21 different families; the final 27 subjects belonged to 18
different families. For the 27 patients who were studied, eyes were analyzed only
if there were visible EZ lines/hyperautofluorescent rings; if there were no EZ
lines/hyperautofluorescent rings, the eye at that time point was not included.

Genetic analysis

DNA was extracted from the blood obtained from patients and was tested for
previously published RP genes of the Chiang panel at Columbia University
Medical Center Department of Pathology and Oregon Health Sciences
University. Parallel sequencing was performed using the Illumina HiSeq platform
with 100 bp paired-end reads, and mutations were confirmed by dideoxy chainterminating sequencing.

Mutation classification

Each patient was assigned a biochemical rhodopsin mutation classification
based on PubMed literature searches for each specific mutation. Biochemical
classifications were found for 32 out of 38 patients. Patients 3 and 4 had
mutations that have not been studied and classified. For patients 6-9, the
mutations were studied in bovine rhodopsin and were not characterized using the
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classification system proposed by Sung et al. (16, 50, 51). Table 2 lists the
mutation classifications as well as their corresponding literature references.
Table 2: Rhodopsin biochemical mutation classification, including excluded patients
Genotype

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

RHO (c.556T>C:p.Ser186Pro)
RHO (c.937-27_-19delCCCTGACTC)
RHO (c.946delT:p.Cys316Alafs*44)
RHO (c.946delT:p.Cys316Alafs*44)
RHO (c.266G>A:p.Gly89Asp)
RHO (c.83A>G:p.Glu28Arg)
RHO (c.328T>C:p.Cys110Arg)
RHO (c.328T>C:p.Cys110Arg)
RHO (c.328T>C:p.Cys110Arg)
RHO (c.568G>A:p.Asp190Asn)
RHO (c.568G>A:p.Asp190Asn)
RHO (c.266G>Ap.Gly89Asp)
RHO (c.1025G>A:p.Thr342Met)
RHO (c.541G>A:p.Glu181Lys)
RHO (c.800C>T:p.267Leu)
RHO (c.316G>A:p.Gly106Arg)
RHO (c.404G>T:p.Arg135Leu)
RHO (c.1040C>T:p.Pro347Leu)
RHO (c.1040C>T:p.Pro347Leu)
RHO (c.1040C>T:p.Pro347Leu)
RHO (c.1040C>T:p.Pro347Leu)
RHO (c.1040C>T:p.Pro347Leu)
RHO (c.1040C>T:p.Pro347Leu)
RHO (c.1040C>T:p.Pro347Leu)
RHO (c.800C>T:p.267Leu)
RHO (c.632A>C:p.His211Pro)
RHO (c.50C>T:p.Thr17Met)
RHO (c.50C>T:p.Thr17Met)
RHO
29
(c.404_405delinsGG>TT:p.Arg135Leu)
30
RHO (c.68C>A:p.Pro23His)
31
RHO (c.68C>A:p.Pro23His)
32
RHO (c.68C>A:p.Pro23His)
33
RHO (c.68C>A:p.Pro23His)
34
RHO (c.68C>A:p.Pro23His)
35
RHO (c.68C>A:p.Pro23His)
36
RHO (c.403C>T:p.Arg135Trp)
37
RHO (c.1040C>T:p.Pro347Leu)
38
RHO (c.1040C>T:p.Pro347Leu)
RHO = rhodopsin; - = mutation class unknown

Mutation class

Reference

IIa
I
IIb
IIa
IIa
IIb
I
IIa
IIa
IIb
III
I
I
I
I
I
I
I
IIa
IIa
IIa
IIa
III

PMID8253795

IIa
IIa
IIa
IIa
IIa
IIa
III
I
I

PMC52606

PMC52606

PMC52606

PMID8253795
PMID8253795
PMC52606
PMC52606
PMID8253795
PMID8253795
PMID8253795
PMC437971
PMC52606
PMC52606
PMC52606
PMC52606
PMC52606
PMC52606
PMC52606
PMID8253795
PMID8253795
PMC52606
PMC52606
PMC437971

PMC52606
PMC52606
PMC52606
PMC52606
PMC52606
PMC437971
PMC52606
PMC52606
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Image acquisition and measurements

Imaging was conducted after adequate pupil dilation (>7 mm) using
phenylephrine hydrochloride (2.5%) and tropicamide (1%). Fundus
autofluorescence (FAF, 488 nm excitation) and horizontal 9 mm SD-OCT images
at the fovea were acquired using the Spectralis HRA+OCT (Heidelberg
Engineering, Heidelberg, Germany) at each visit. OCT imaging was assisted by
eye-tracking technology that enables accurate and reproducible scans at the
same location on the fovea across multiple visits. The images were recorded with
a 30-degree field of view; in cases where the rings were too large to be
visualized with the 30-degree field of view, scans with a 55-degree field of view
were also captured.

The ellipsoid zone line widths, and horizontal and vertical diameters of the
hyperautofluorescent ring were manually measured using the built-in measuring
tool provided by the Spectralis software. The ellipsoid zone line width was
measured between the nasal and temporal limits of the ellipsoid zone layer using
the horizontal foveal scan on SD-OCT. The external border of the
hyperautofluorescent ring was used to determine diameter length, as it is more
clearly defined and easily visualized compared to the internal border. The
horizontal diameter is oriented along the axis formed by the center of the fovea
and the center of the optic disc. The vertical diameter is defined as the length of
the line between the external ring border, perpendicular to the horizontal
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diameter and passing the center of the fovea (Figure 3). For each parameter
(ellipsoid zone line width, horizontal and vertical diameters of the autofluorescent
ring), two measurements were taken by the author (L.C.) four weeks apart for
each studied image in order to assess for test-retest reliability. Cystoid macular
edema (CME) was also noted if it significantly present in the OCT images. The
hyperautofluorescent rings seen on FAF were qualitatively categorized as either
typical (uniformly round, ellipsoidal rings) or atypical (any ring that deviates from
the typical morphology). Figure 4 shows an example of typical vs. atypical ring
morphology.

Figure 3. Short wavelength fundus autofluorescence (SW-FAF) image of left eye. Red: horizontal
diameter measurement; blue: vertical diameter measurement.
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Figure 4. Examples of various forms of hyperautofluorescent ring morphology on fundus
autofluorescence (FAF) imaging. Left: typical, uniformly round, ellipsoidal ring. Middle: atypical,
irregularly shaped autofluorescence surrounded by regions of atrophy. Right: atypical, arcuate
autofluorescence in the inferior macula.

Electroretinography

Full-field electroretinography (ffERG) was performed using disposable corneal
low-impedance corneal DTL electrodes and the Diagnosys Espion
Electrophysiology System (Diagnosys LLC, Lowell, MA, USA) on both eyes in
accordance to the International Society for Clinical Electrophysiology of Vision
(ISCEV) standards. Dark-adapted 0.01 cd·s·m^-2 stimulus strength (rod
response), dark-adapted 3.0 cd·s·m^-2 (combined rod-cone response), lightadapted 3.0 cd·s·m^-2 (single-flash cone response), and light-adapted 3.0
cd·s·m^-2 flicker (30 Hz flicker) ERG recordings were obtained. The patients
were dark-adapted for a minimum of 20 minutes before the scotopic ERG
measurements and were light-adapted for a minimum of 10 minutes prior to the
photopic ERG tests. For patients with 30 Hz flicker amplitudes less than 5 uV or
who were predicted to have less than 5 uV based on clinical examination, bipolar
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Burian-Allen contact lens electrodes were used with narrow bandpassed filtering
and computed averaging in order to minimize electrical artifacts and noise when
measuring small amplitude cone responses (52). The 30 Hz flicker data were
used for analysis as it is a commonly used outcome measure of visual function in
RP patients (52). Because rod function is usually the first to be affected in RP,
the scotopic ERG responses are typically markedly diminished at presentation,
making the 30 Hz flicker cone ERG response (Figure 5) a useful prognostic
marker of functional vision in everyday activities.

30 Hz Flicker

Amplitude

Figure 5. 30 Hz flicker waveform with peak, trough, and amplitude marked (green).
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Statistical analysis

For each patient in the cohort, measurements of EZ line width and horizontal and
vertical hyperautofluorescent ring diameters were obtained from SD-OCT and
FAF images, respectively, from the most recent visit and the first visit if the
patient was seen more than once in our clinic. The widths and diameters were
measured by the author (L.C.) four weeks apart to determine test-retest
reliability. The intraclass correlation coefficient (ICC) was calculated for each
structural parameter to determine the reliability of the test-retest measurements.
To calculate the correlation between each pair of parameters, the Pearson
correlation coefficient was used based on the average of the two test-retest
measurements. The rate of progression was calculated for each parameter by
taking the difference between the value from the most recent visit and the value
from the first visit, divided by the length of follow-up. In order to test for symmetry
of the right and left eyes (i.e., whether the progression rates of the right and left
eyes were similar), the difference in progression rates between the eyes was
compared to the variability of test-retest measurements of the right eye. All
statistical analyses were performed using Stata 12.1 (StataCorp LP, College
Station, TX).
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Results

Clinical data

A total of 38 patients were identified as having adRP caused by mutations in the
RHO gene. 11 patients were excluded from the study as a result of having
advanced-stage disease with no visible EZ line at any time point, leaving 27
patients in our analysis. Sixteen (59.3%) patients were female and eleven
(40.7%) were male. The average age of patients at the initial visit was 44.0 years
(standard deviation 17.7 years, range 15-78 years). Sixteen patients had
measurements from more than one clinic visit, while eleven patients were
examined at only one clinic visit and thus did not receive any analysis for disease
progression. The age distribution of patients with data from multiple clinical visits
is shown in Table 3. The average length of follow-up for patients with more than
one visit was 4.3 years (standard deviation 2.8 years). A total of 20 patients had
typical symmetric ellipsoid-shaped hyperautofluorescent rings, and 7 had atypical
rings that deviated from the typical morphology. Six patients were observed to
have cystoid macular edema (CME) in either eye. The results are summarized in
Table 4.

Table 3: Age distribution of subjects with multiple clinical visits
n

Mean age (years)

Standard deviation

16

43.6

19.4

Minimum
15

25th
25.5

Quantiles
Median 75th
43.5
57.5

Maximum
78
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Table 4. Genotype, demographic, and clinical characteristics of study subjects
ID

Age

Sex

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

23
71
44
46
16
69
15
59
43
56
39
66
78
37
34
28
46
49
19
28
56

F
M
F
F
F
F
M
M
M
F
F
M
M
F
F
M
M
M
M
F
F

Genotype

Years of
followup

Typical
ellipsoidal
hyperautofluorescent ring

Mutation
class

CME

RHO (c.937-27_-19delCCCTGACTC)
6.8
+
I
RHO (c.946delT:p.Cys316Alafs*44)
N/A
+
RHO (c.266G>A:p.Gly89Asp)
0.5
+
IIb
+
RHO (c.328T>C:p.Cys110Arg)
2.8
+
N/A
RHO (c.328T>C:p.Cys110Arg)
2.8
+
N/A
RHO (c.328T>C:p.Cys110Arg)
6.4
N/A
RHO (c.568G>A:p.Asp190Asn)
3
+
IIa
RHO (c.568G>A:p.Asp190Asn)
7
+
IIa
RHO (c.266G>Ap.Gly89Asp)
7
IIb
+
RHO (c.1025G>A:p.Thr342Met)
8.3
+
I
RHO (c.541G>A:p.Glu181Lys)
0.1
IIa
RHO (c.800C>T:p.267Leu)
8
+
IIa
RHO (c.316G>A:p.Gly106Arg)
5.7
+
IIb
+
RHO (c.404G>T:p.Arg135Leu)
3.7
+
III
RHO (c.1040C>T:p.Pro347Leu)
+
I
RHO (c.1040C>T:p.Pro347Leu)
+
I
RHO (c.1040C>T:p.Pro347Leu)
+
I
RHO (c.632A>C:p.His211Pro)
+
IIa
RHO (c.50C>T:p.Thr17Met)
+
IIa
RHO (c.50C>T:p.Thr17Met)
4.2
+
IIa
RHO
1.7
III
(c.404_405delinsGG>TT:p.Arg135Leu)
22 37
F
RHO (c.68C>A:p.Pro23His)
+
IIa
23 56
F
RHO (c.68C>A:p.Pro23His)
+
IIa
24 32
F
RHO (c.68C>A:p.Pro23His)
+
IIa
25 56
M
RHO (c.68C>A:p.Pro23His)
IIa
+
26 61
F
RHO (c.68C>A:p.Pro23His)
IIa
27 23
F
RHO (c.1040C>T:p.Pro347Leu)
0.2
+
I
RHO = rhodopsin; CME = cystoid macular edema; N/A = mutation class unknown; + = finding is
present

Reliability of measurements

The test-retest reliability was assessed using the intraclass correlation coefficient
(ICC) for each of the three measurement parameters. Within each measurement
parameter, the data for both eyes at all time points were pooled. The ICC for the
ellipsoid zone line width was 0.9989, ICC for the horizontal diameter was 0.9889,
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and the ICC for the vertical diameter was 0.9771. Graphs showing the
intraobserver reliability of the three parameters for each eye are shown in Figure
6.

To determine the strength of linear association between each of the three
imaging parameters, the Pearson correlation coefficient (two-tailed, α = 0.05)
was calculated. The analysis revealed a high degree of correlation between each
pair of parameters (scatterplots shown in Figure 7): r = 0.9325 (p < 0.0001) for
the ellipsoid zone line and horizontal diameter measurements, r = 0.9081 (p <
0.0001) for the ellipsoid zone line and vertical diameter measurements, and r =
0.9630 (p < 0.0001) for the horizontal diameter and vertical diameter
measurements.
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Figure 6. Intraobserver reliability of ellipsoid zone line widths, hyperautofluorescent horizontal
ring diameters, and vertical ring diameters of right (OD) and left (OS) eyes in a cohort of 27
patients with autosomal dominant retinitis pigmentosa. Measurements for each parameter
were taken four weeks apart. Line of equality shown.
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Figure 7. Correlation of ellipsoid zone
line widths, hyperautofluorescent
horizontal ring diameters, and vertical
ring diameters. Scatterplots show EZ
line widths compared to horizontal
width diameters (top), EZ line widths
compared to vertical diameters
(middle), and horizontal diameters
compared to vertical diameters
(bottom).
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Structural progression rate

Using the structural measurements for patients with multiple time points, the
progression rate for each parameter was calculated separately for each eye
(Table 5). The progression rates were calculated with p-values using the null
hypothesis μ = 0. All progression rates were found to be negative, indicating a
decline in length over time. The mean rates of decline for the EZ line in the right
eye was 208.7 μm/year (standard error = 49.8, p = 0.0008), EZ line in the left eye
was 96.6 μm/year (standard error = 37.7, p = 0.0248), horizontal diameter in the
right eye was 109.5 μm/year (standard error = 36.2, p = 0.0097), horizontal
diameter in the left eye was 138.1 μm/year (standard error = 46.3, p = 0.0124),
vertical diameter in the right eye was 114.2 μm/year (standard error = 30.5, p =
0.0025), and vertical diameter in the left eye was 101.5 μm/year (standard error =
31.6, p = 0.0083). The Wilcoxon signed-rank test was also performed for each
imaging parameter for each eye as an alternative to the Student’s t-test without
assuming a normal distribution for the data (Table 6).
Table 5: Progression rates of the three measured imaging parameters for each eye
Parameter

n

Mean
change
(μm/yr)

Standard
error

Minimum
(μm/yr)

Median
(μm/yr)

Maximum
(μm/yr)

EZ line width OD
16
-208.7
49.8
-742.9
-172.8
-7.9
EZ line width OS
13
-96.6
37.7
-365
-86.9
173.9
Horizontal diameter
-76.8
14
-109.5
36.2
-466.4
72.6
OD
Horizontal diameter
-70.0
12
-138.1
46.3
-445.4
2.8
OS
Vertical diameter OD 14
-114.2
30.5
-411.3
-101.9
25.3
Vertical diameter OS 12
-101.5
31.6
-386.2
-80.3
16.2
EZ = ellipsoid zone; OD = right eye; OS = left eye; rates = μm per year; negative rate =
decrease in length; positive rate = increase in length
*p-value calculated using one-sample Student’s t-test with null hypothesis μ = 0

p-value*

0.0008
0.0248
0.0097
0.0124
0.0025
0.0083

31

Table 6: p-values from Wilcoxon signed-rank test of progression rates for three imaging
parameters
Parameter

p-value*

EZ line width OD
0.0004
EZ line width OS
0.0192
Horizontal diameter OD
0.0043
Horizontal diameter OS
0.0029
Vertical diameter OD
0.0023
Vertical diameter OS
0.0047
EZ = ellipsoid zone; OD = right eye; OS = left eye
*p-value calculated using Wilcoxon signed-rank test with null hypothesis μ = 0

After the rates from both eyes were pooled to obtain an overall progression rate
for each measurement, the mean rate of decline for the EZ line was 158.5
μm/year (standard error = 33.4, p < 0.0001), horizontal diameter was 122.7
μm/year (standard error = 28.5, p = 0.0002), vertical diameter was 108.3 μm/year
(standard error = 21.6, p < 0.0001) (Table 7). Converting the progression rates in
terms of percentages of the mean value at the initial visit yields an average
yearly progression rate (decline) of 8.4% for the ellipsoid zone line, 3.5% for the
horizontal diameter, and 3.9% for the vertical diameter.

Table 7: Overall progression rates of the three measured imaging parameters, both eyes
combined
Parameter

n

Mean change (μm/yr)

Standard error

p-value*

EZ line width
29
-158.5
33.4
<0.0001
Horizontal diameter
26
-122.7
28.5
0.0002
Vertical diameter
26
-108.3
21.6
<0.0001
EZ = ellipsoid zone; rates = μm per year; negative rate = decrease in length; positive rate =
increase in length
*p-value calculated using one-sample Student’s t-test with null hypothesis μ = 0
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Asymmetry of disease severity and progression rates between both eyes

Since some of the subjects exhibited markedly different measurements between
left and right eyes at baseline, the asymmetry of disease severity and
progression rate between both eyes was assessed. For ellipsoid zone
measurements, we first calculated the variability of the absolute differences
between the right and left eyes using the average of the two intraobserver
measurements for all time points (standard deviation = 506.8 μm). Comparison of
this value to the variability of the absolute differences between the test and retest
ellipsoid zone measurements of the right eye for all time points (standard
deviation = 46.7 μm) shows that there is a greater amount of variability between
eyes than the test-retest measurements of one eye.

Next, the 95th percentile of absolute differences in EZ line progression rates
between the test and retest measurements of the right eye was calculated (110.2
μm/year) in order to set the threshold for quantifying the number of patients who
had significant differences in progression rates between their left and right eyes.
23% (3/13) of the subjects with progression data for both eyes were found to
have absolute differences in progression rates between eyes that exceeded the
110.2 μm/year threshold.

Repeating the asymmetry analysis for the horizontal diameter measurements, we
found that the variability between the right and left eyes (standard deviation
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= 968.2 μm) was greater than the variability between the test and retest
measurements of the right eye (standard deviation = 184.0 μm). The 95th
percentile of absolute differences in horizontal diameter progression rates
between the test and retest measurements of the right eye was 173.7 μm/year.
17% (2/12) of the subjects with progression data for both eyes had differences in
horizontal diameter progression rates between eyes that exceeded the 95th
percentile threshold.

For the vertical diameter, the variability between the right and left eyes (standard
deviation = 452.0 μm) was greater than the variability between the test and retest
measurements of the right eye (standard deviation = 214.9 μm). 25% (3/12) of
the subjects with progression data for both eyes were found to have significantly
different vertical diameter progression rates between eyes that exceeded the
95th percentile of absolute differences in progression rates between the test and
retest measurements of the right eye (117.5 μm/year).

Functional progression rate

ERG data was available for ten subjects, of which three patients had longitudinal
measurements from multiple visits. The average length of ERG follow-up was 2.8
years. Table 8 summarizes the 30 Hz flicker ERG test results. For the initial visit,
the mean 30 Hz flicker amplitude was 22.0 μV (standard error = 7.0) in the right
eye and 23.9 μV (standard error = 7.7) in the left eye. The mean change in
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amplitude of the 30 Hz flicker test was an increase in 3.9 μV per year (standard
deviation = 2.8 μV).

Table 8: 30-Hz flicker amplitudes for subjects with ERG data
Time point 1

ID

Age

Length of
ERG followup (years)

OD 30 Hzflicker
amplitude
(μV)

OS 30 Hzflicker
amplitude
(μV)

Time point 2
OD 30 Hzflicker
amplitude
(μV)

OS 30 Hzflicker
amplitude
(μV)

OD mean
change (μV
per year)

OS mean
change
(μV per
year)

1
23
6.8
31
36
40
50
1.3
2.1
6
69
0.7
0.2
7
15
70
70
11
39
3
2
13
78
0.6
21
22
23
25
3.3
5
14
37
4.8
2.6
20
28
1.1
40
42
50
45
9.1
2.7
21
56
1.5
25
32
15
13
29
23
33
27
ERG = electroretinography; OD = right eye; OS = left eye; mean change was calculated only for
subjects with multiple ERG time points; time point 1 = initial visit; time point 2 = most recent
visit

Mutation class-specific measurements and progression rates

Subjects were classified by rhodopsin biochemical mutation class based on a
literature search of their genotypes, as seen in Table 2. For the 27 subjects that
were analyzed, stratification into five groups was performed: class I, class IIa,
class IIb, class III, and unknown class. The mean structural measurements for
each eye and time point were calculated for each mutant group, and the results
are summarized in Tables 9, 10, 11, 12, 13. Using these measurements, we
calculated the rate of structural progression for each eye and each mutation
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class (Table 14). The overall rate of structural progression after combining both
eyes was also calculated for each mutation class (Table 15).

Table 9. Class I mutation mean structural measurements, both time points
OD
n

Mean

OS
SD

n

Mean

SD

Time point 1
3
3540.3 2464.1
3
3388.8
2564.5
Time point 2
3
2697.8 2879.9
3
3144.8
2297.0
Horizontal
Time point 1
2
4396.3 2562.2
2
4317.3
2826.7
diameter
Time point 2
2
3740.8 3101.0
2
3718.8
30147.3
Vertical
Time point 1
2
4313.3 2845.0
2
3919.0
2852.5
diameter
Time point 2
2
2916.3 2620.9
2
2870.5
2601.5
EZ = ellipsoid zone; OD = right eye; OS = left eye; SD = standard deviation; time point 1 = initial
visit; time point 2 = most recent visit. All units are in μm.
EZ line width

Table 10. Class IIa mutation mean structural measurements, both time points
OD
n

Mean

OS
SD

n

Mean

SD

Time point 1
5
2276.6 1892.1
3
3539.5
3187.8
Time point 2
5
1991.5 1675.6
3
3144.8
2971.3
Horizontal
Time point 1
4
3348.0 2070.7
3
3799.0
2736.0
diameter
Time point 2
4
2985.3 1694.2
3
3467.0
2836.9
Vertical
Time point 1
4
2730.6 1795.1
3
3433.8
2671.9
diameter
Time point 2
4
2305.5 1640.6
3
3129.5
2845.4
EZ = ellipsoid zone; OD = right eye; OS = left eye; SD = standard deviation; time point 1 = initial
visit; time point 2 = most recent visit. All units are in μm.
EZ line width

Table 11. Class IIb mutation mean structural measurements, both time points
OD
n

Mean

OS
SD

n

Mean

SD

Time point 1
3
2805.7 1450.8
3
2443.2 1162.7
Time point 2
3
2192.2
766.1
3
2034.0
802.3
Horizontal
Time point 1
3
4023.5
968.6
3
3444.3
421.9
diameter
Time point 2
3
3413.5
698.2
3
3178.8
303.8
Vertical
Time point 1
3
3022.5
704.0
3
2750.7
665.5
diameter
Time point 2
3
2774.5
639.0
3
2582.7
383.0
EZ = ellipsoid zone; OD = right eye; OS = left eye; SD = standard deviation; time point 1 = initial
visit; time point 2 = most recent visit. All units are in μm.
EZ line width
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Table 12. Class III mutation mean structural measurements, both time points
OD
n

Mean

OS
SD

n

Mean

SD

EZ line
Time point 1 2
1393.3
801.5
1
1505.0
width
Time point 2 2
899.3
1271.7
1
1569.5
Horizontal Time point 1 2
1920.0
856.3
1
2190.0
diameter
Time point 2 2
1863.0
770.8
3
2200.5
Vertical
Time point 1 2
1668.3
332.0
1
1805.0
diameter
Time point 2 2
1687.5
437.7
1
1778.0
EZ = ellipsoid zone; OD = right eye; OS = left eye; SD = standard deviation; time point 1 = initial
visit; time point 2 = most recent visit; - = not available. All units are in μm.

Table 13. Mean structural measurements for unknown mutation class, both time points
OD
n

Mean

OS
SD

n

Mean

SD

EZ line
Time point 1 3
2238.5
1595.9
3
2579.5
2134.7
width
Time point 2 3
1679.8
1385.9
3
1896.3
1988.4
Horizontal Time point 1 3
3409.5
1437.2
3
3682.8
1578.4
diameter
Time point 2 3
3142.0
1525.7
3
2437.0
2404.2
Vertical
Time point 1 3
2794.8
1320.8
3
3029.2
1256.6
diameter
Time point 2 3
2409.8
1451.2
1
1998.5
2015.5
EZ = ellipsoid zone; OD = right eye; OS = left eye; SD = standard deviation; time point 1 = initial
visit; time point 2 = most recent visit; - = not available. All units are in μm.

Table 14. Rate of structural progression for each mutation class, right vs. left eye
OD
Mutation class

n

Mean

OS
SD

n

Mean

SD

Class I
3
-346.7
348.1
3
22.0
135.6
Class IIa
5
-107.2
80.15
3
-108.4
90.8
EZ line
Class IIb
3
-237.6
203.7
3
-151.3
120.1
width
Class III
2
-263.4
311.1
1
17.35
Unknown
3
-174.6
115.2
3
-186.7
158.8
Class I
2
-81.8
59.2
2
-77.2
18.1
Class IIa
4
-103.7
132.7
3
-73.0
96.2
Horizontal
Class IIb
3
-246.5
219.5
3
-178.8
229.0
diameter
Class III
2
-14.8
23.0
1
2.8
Unknown
3
-62.0
32.3
3
-250.1
195.7
Class I
2
-187.2
55.7
2
-141.3
52.8
Class IIa
4
-102.9
90.2
3
-62.3
72.3
Vertical
Class IIb
3
-169.1
217.6
3
-48.2
60.4
diameter
Class III
2
-3.6
40.8
1
-7.3
Unknown
3
-99.6
12.1
3
-198.9
170.1
EZ = ellipsoid zone; OD = right eye; OS = left eye; SD = standard deviation; time point 1 = initial
visit; time point 2 = most recent visit; - = not available. All units are in μm.
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Table 15. Rate of structural progression for each mutation class, all eyes
Mutation class

n

Mean

SD

p-value†

Class I
6
-162.3
310.8
0.2569
Class IIa
8
-107.7**
77.6
0.0057
EZ line
Class IIb
6
-194.5*
156.9
0.0289
width
Class III
3
-169.8
273.3
0.3943
Unknown
6
-180.6*
124.2
0.0162
Class I
4
-79.5*
35.8
0.0212
Class IIa
7
-90.6
110.2
0.0727
Horizontal
Class IIb
6
-212.7
204.0
0.0511
diameter
Class III
3
-8.9
19.7
0.5146
Unknown
6
-156.1
162.3
0.0651
Class I
4
-164.2**
51.6
0.0079
Class IIa
7
-85.5*
79.3
0.0290
Vertical
Class IIb
6
-108.6
157.4
0.1519
diameter
Class III
3
-4.8
29.0
0.8004
Unknown
6
-149.2*
120.8
0.0292
EZ = ellipsoid zone; SD = standard deviation. All units are in μm. †p-value calculated using onesample Student’s t-test with null hypothesis μ = 0. * = p-value < 0.05; ** = p-value < 0.01

Ring morphology analysis

The presence of a typical ellipsoidal ring or an atypical ring on fundus
autofluorescence was noted for each patient (Table 4). The impact of the
presence of a typical ring was examined by comparing the mean progression
rates in the subgroup of patients with typical rings and patients with atypical
rings. For ellipsoid zone line progression rates, patients with atypical rings (n = 6)
had an average rate of -154.0 μm/year (standard deviation = 173.1 μm/year).
Patients with a typical ring (n = 23) had a mean rate of -159.6 μm/year (standard
deviation = 185.4 μm/year). A two-sample Student’s t-test (two-tailed, equal
variance) showed a p-value of 0.947, indicating no significant difference in the
progression rates between both groups.
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For horizontal diameter rates, patients with atypical ring morphology (n = 5) had a
mean change of -113.5 μm/year (standard deviation = 187.8 μm/year), and those
with typical ring morphology (n = 21) had an average rate of -124.9 μm/year
(standard deviation = 138.7 μm/year). No significant difference in rates was
found on the Student’s t-test (p-value = 0.878).

Examining the vertical diameters, we found that patients with atypical rings (n =
5) had an average progression rate of -96.2 μm/year (standard deviation = 167.4
μm/year), and patients with typical rings (n = 21) progressed by -111.2 μm/year
(standard deviation = 97.4 μm/year). Similar to the ellipsoid zone and horizontal
diameter analyses, no significant difference in vertical diameter progression
between both subgroups was found using the t-test (p-value = 0.790).
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Discussion

Overall, this study of progression in retinitis pigmentosa patients with autosomal
dominant rhodopsin mutations demonstrates that ellipsoid zone line widths as
measured by SD-OCT and hyperautofluorescent ring diameters measured by
SW-FAF can be used to detect progression in RP, corroborating previous studies
of disease progression in RP cohorts with varying mean lengths of follow-up (39,
53-55). While most studies had a genetically heterogeneous group of RP patients
with X-linked, syndromic, autosomal dominant, and autosomal recessive RP, this
study examined only those with confirmed autosomal dominant RHO mutations.
The mean length of follow-up for our patients was 4.3 years (SD = 2.8 years),
while Sujirakul et al. had a 2-year mean follow-up, Takahashi et al. had an
average follow-up of 4.5 years, and Cabral et al. had a mean length of 3.1 years
(53-55). The mean rates of decline were 158.5 μm/year (8.4%) for EZ line widths,
122.7 μm/year (3.5%) for horizontal diameters, and 108.3 μm/year (3.9%) for
vertical diameters, which are comparable to rates found in previous studies (39,
53-57).

Furthermore, our results show that the three structural parameters correlate well
with each other (r = 0.9325 for EZ line and horizontal diameter; r = 0.9081 for EZ
line and vertical diameter; r = 0.9630 for horizontal and vertical diameters) and
have a high degree of intraobserver reliability (ICC = 0.9989 for EZ line, ICC =
0.9889 for horizontal diameter, ICC = 0.9771 for vertical diameter). These
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findings confirm that structural measurements of disease progression using SWFAF and SD-OCT imaging modalities are reliable and objective methods of
assessing the patient’s state of disease.

Asymmetry of progression in EZ line widths, horizontal diameters, and vertical
diameters between the left and right eyes was also observed. 23% of subjects
had asymmetry in EZ line progression, 17% had asymmetry in horizontal
diameter progression, and 25% had asymmetry in vertical diameter progression.
These rates are slightly higher than rates of asymmetry found in other studies.
One study found an overall proportion of approximately 20% of patients with
significant asymmetry between both eyes, though the asymmetry was seen only
in EZ line progression and not in horizontal or vertical diameter progression of
the ring (54). Another study of patients with Usher syndrome found only a 10%
rate of hyperautofluorescent ring asymmetry (57). A possible cause for the
differences in observed asymmetry may be that different forms of RP, whether by
inheritance pattern or gene mutation, are more strongly associated with
asymmetry than others. It has been observed that some genes (RHO, PRPF8)
implicated in autosomal dominant RP may exhibit variable expressivity (58, 59),
and we theorize that this variability may account for the asymmetry to some
degree. A better understanding of asymmetry in RP patients will be needed to
properly enroll subjects and monitor disease progression in future clinical trials.
This is also particularly important because gene therapy trials often test
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treatment in one eye while keeping the untreated eye as an internal control, and
asymmetry may skew results.

Functional progression using the 30 Hz flicker amplitudes on electroretinography
was also examined. The 30 Hz flicker test was chosen as a useful outcome to
measure given that scotopic ERG responses are commonly extinguished in RP
patients at the time of presentation. The flicker amplitudes were also used as the
main outcome measure in the landmark trial studying the effects of vitamin A and
E supplementation in patients with RP (60). A mean positive change (3.9
μV/year) was observed, which is unexpected as one would expect retinal function
to decline over time in a fashion similar to the structural measurements. This
finding is likely due to the high test-retest variability of ERG measurements (e.g.,
recording conditions, electrodes, operator technique), relatively stable
progression of function in slow-progressing variants of RP, and our small sample
size (n = 3). Of the two clinical phenotypes, our few patients with longitudinal
ERG data may likely belong to the class B phenotype, characterized by slower
and less severe progression of disease. Studies on different types of
retinopathies have suggested that the 30 Hz flicker amplitude may be a less
sensitive, highly variable signal that does not correlate well with disease severity;
instead, they propose that the 30 Hz flicker implicit time may be a more reliable
marker (61, 62).
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RP is genetically heterogeneous with each gene being identified as having
multiple possible mutations that affect gene/protein function through distinct
mechanisms. Because of this, we sought to classify each subject by their
rhodopsin mutation class based on their genotype and prior in vitro biochemical
studies of rhodopsin mutants. The mean rates of structural progression were
calculated for each mutant class. However, since the size of the cohort was small
(n = 27), dividing the cohort further by mutation class resulted in subgroups that
were even smaller, highly variable, and too underpowered for any statistically
significant conclusions to be drawn from. Some of the patients (n = 3) had
mutations that were still unclassified in the literature, suggesting further work to
be done in studying the molecular pathogenesis of newly discovered mutations
and their effects on protein structure.

In our subjects, two patterns of hyperautofluorescent rings could be discerned:
typical/ellipsoidal and atypical. These regions of maximal intensity on fundus
autofluorescence with 488 nm excitation are thought to correlate to areas of the
retina containing an abundance of lipofuscin through active degeneration of the
photoreceptors and subsequent increased phagocytosis by the RPE. Thus, the
ring may mark the boundary between healthy and diseased retina, as well as the
limits of the patient’s visual field. 26% (7/27) of our cohort had atypical rings, and
we were interested in whether the morphology of the ring was associated with
the rate of progression. No statistically significant differences were found
between patients with typical and atypical morphology regarding EZ line width,
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horizontal diameter, and vertical diameter progression rates. The small size of
the atypical ring group may have contributed to this finding; increasing the
sample size in future studies would allow for better detection of differences if they
do exist.

The significance of determining the progression rates in this subset of adRP
patients is three-fold: 1) this data would allow clinicians to more accurately
counsel patients with these specific mutations regarding their prognosis, 2) future
gene therapy trials will need to have an objective baseline of natural history
disease progression for patients with their target genotype in order to determine
efficacy of treatment, and 3) any results from a subset of the cohort that are
unexpected or deviate from the rest of the subjects may provide the basis on
which to perform further studies to elucidate mechanisms of pathogenesis and
other factors that influence disease severity.

Notwithstanding its potential significance, this study has certain limitations. The
retrospective nature of the study may introduce selection and information biases,
as well as result in heterogeneity of the types of data/measurements at our
disposal. The inclusion-exclusion criteria and subsequent subgroup classification
restricted the analysis to a small cohort of patients, which decreases the
statistical power. Patients with severe end-stage RP were unable to be studied
due to lack of a discernable EZ line on SD-OCT. Only three subjects had
longitudinal ERG data, which limits any statistically significant conclusions to be
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drawn regarding functional progression. The lengths of follow-up for patients with
imaging data were also variable, ranging from two months to 8.3 years. Four
patients had mutations that were unable to be classified by rhodopsin mutation
class. Finally, the majority of subjects had typical ellipsoidal hyperautofluorescent
rings, leaving only seven patients with atypical ring morphology,

Using a combination of objective measures of visual function like the ERG and
non-invasive imaging modalities such as OCT and FAF has good utility in
monitoring disease progression in RP. Each modality has its own set of
advantages and drawbacks. For example, electrophysiology can be used to
detect early-stage disease since ERG abnormalities typically precede any
structural changes on funduscopic and imaging exams (63). ERGs can also be
used in determining the long-term visual prognosis of RP patients from a single
visit based on the amplitudes of the 30 Hz flicker test (52). However, as
previously mentioned, some of the drawbacks that make it difficult to effectively
implement include high sensitivity to electrical noise through electronic
interference, artifacts produced through blinking and eye movements, variability
of waveforms produced depending on electrode positioning, relatively long
duration of exam (~30-60 minutes), and requirement of anesthesia for use in
pediatric populations. On the other hand, structural imaging with OCT and FAF
can provide high-resolution images of the posterior pole of the retina with a very
low degree of invasiveness and minimal test-retest variability. FAF imaging can
provide data about metabolism and RPE lipofuscin accumulation that may not be
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visible to the naked eye on fundus examination, and OCT enables direct
visualization of the EZ line, whose characteristics such as integrity, intensity, and
width have been correlated with different retinal disease processes. These
imaging modalities are limited by their inability to scan beyond the central retina,
the requirement of an intact EZ line (precluding patients with advanced-stage
disease from analysis), and lack of direct assessment of function, which is
ultimately what affects quality of life for patients. Nevertheless, structural and
functional tests can complement each other to provide valuable data about the
retina’s overall health and function.

Looking forward, this study can be the basis of follow-up studies with increased
sample sizes and power. The promising field of gene therapy for the treatment of
inherited retinal degenerations may finally bring treatment options to patients who
are eagerly anticipating clinical trials that will first need to characterize
progression rates of disease. Future studies with sufficiently large enough
cohorts can utilize mixed effect models to assess the effects of other variables
such as disease stage, sex, and age on disease progression. They can also
continue to look for the effects of mutation class and ring morphology on rates.
Although rhodopsin mutations account for a large portion of autosomal dominant
RP cases, the disease is relatively rare and the specific mutations even more so.
A multicenter study would help increase the cohort size and improve the
statistical confidence of any analyses, although care will have to be taken to
ensure standardized imaging equipment and techniques. Studies with a longer
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follow-up duration would also be helpful in capturing changes in rates over more
stages of disease.
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